Centers for Disease Control and Prevention: Tuberculosis trials

The registry lists 23 Tuberculosis studies with Centers for Disease Control and Prevention as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 1 1Phase 2 6Phase 3 6Phase 4 3No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• An Evaluation of Traditional Directly Observed Therapy (DOT) and Electronic DOT for TB TreatmentCompletedNCT03266003Not applicableResults posted
• Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of TuberculosisCompletedNCT02563327Phase 3Results posted
• TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening RegimensCompletedNCT02410772Phase 3Results posted
• Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOTCompletedNCT01582711Phase 3Results posted
• TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB InfectionCompletedNCT00164450Not applicableResults posted
• Study of Limited Versus Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in BotswanaCompletedNCT00164281Phase 4Results posted
• Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis InfectionCompletedNCT00023452Phase 3Results posted
• Evaluating Accuracy, Impact, and Operational Challenges of GeneXpert Use for TB Case Finding Among HIV-infected PersonsCompletedNCT02538952Phase 4
• Brief Bactericidal Activity of Anti-Tuberculosis DrugsCompletedNCT02236078Phase 1
• Evaluation of an Enhanced Tuberculosis Infection Control Intervention in Healthcare Facilities in Vietnam and ThailandCompletedNCT02073240
• Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to TuberculosisCompletedNCT01622140
• TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB TreatmentCompletedNCT00164463Phase 2
• TBTC Study 28: Moxifloxacin Versus Isoniazid for TB TreatmentCompletedNCT00144417Phase 2
• TBTC Study 27: Moxifloxacin vs Ethambutol for TB TreatmentCompletedNCT00140309Phase 2
• TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB TreatmentCompletedNCT00023439
• TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of TuberculosisCompletedNCT00023426Phase 2
• TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily EfavirenzCompletedNCT00023413Phase 2
• TBTC Study 23B:Intensive PK of the Nelfinavir Rifabutin Interaction in Patients With HIV-TBCompletedNCT00023400Phase 4
• TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl RifapentineCompletedNCT00023387Not applicable
• TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or IntoleranceCompletedNCT00023374Not applicable
• TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based RegimenCompletedNCT00023361Not applicable
• TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in HIV-TBCompletedNCT00023348Phase 2/3
• TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of TuberculosisCompletedNCT00023335Phase 3